Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Geovax LabsGOVX +11.28%22 3-Year ROIIC % is 920.19 as of Dec. 2025. GuruFocus rates GOVX with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 1,323 Biotechnology companies, Geovax Labs ranks better than 93.95% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Geovax Labs's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 920.19%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Geovax Labs's 3-Year ROIIC % or its related term are showing as below:
GOVX's 3-Year ROIIC % is ranked better than 93.95% of 1323
companies
in the Biotechnology industry
Industry Median: -4.85
vs GOVX: 920.19
Geovax Labs (NAS:GOVX) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Geovax Labs 3-Year ROIIC % Related Terms
Geovax Labs 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Geovax Labs's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GOVX vs XBIO, MTVA, ACXP: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Geovax Labs's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Geovax Labs 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Geovax Labs's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Geovax Labs's 3-Year ROIIC % falls into.
Geovax Labs's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -21.639 (Dec. 2025) - -14.029 (Dec. 2022) )
/
( 1.582 (Dec. 2025) - 2.409 (Dec. 2022) )
=
-7.61
/
-0.827
=
920.19%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Geovax Labs (GOVX) has a 3-Year ROIIC % of 920.19 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Geovax Labs and its competitors. According to the industry distribution chart, Geovax Labs ranks #80 out of 1323 companies in the Biotechnology industry, placing it in the top 6%.
Is Geovax Labs' 3-Year ROIIC % too high?
Geovax Labs' current 3-Year ROIIC % is 920.19. Based on the distribution chart, Geovax Labs ranks #80 out of 1323 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Geovax Labs has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Geovax Labs' 3-Year ROIIC % compare to XBIO and MTVA?
According to the Biotechnology industry distribution chart, Geovax Labs ranks #80 out of 1323 companies for 3-Year ROIIC %. This places Geovax Labs in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Geovax Labs and its competitors. Geovax Labs's current 3-Year ROIIC % is 920.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geovax Labs stock overvalued right now?
Geovax Labs (GOVX) has a current 3-Year ROIIC % of 920.19. The current 3-Year ROIIC % is 920.19. Geovax Labs' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Geovax Labs (GOVX), the current 3-Year ROIIC % is 920.19 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
22GF Score
Get the complete analysis for GOVX
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GOVX has been successfully added to your 
